Navigation Links
Esperance Pharmaceuticals Completes $7.5 Million Series B Financing

BATON ROUGE, La., June 1, 2011 /PRNewswire/ -- Esperance Pharmaceuticals, Inc. today announced the first closing of a $7.5 million Series B financing. Proceeds from the Series B will support further clinical development of EP-100, the lead cancer-targeting drug candidate from Esperance's Cationic Lytic Peptide (CLYP™) platform technology and the continued expansion of the Company's pipeline. Sanofi led the Series B funding with an investment of $4.5 million, which includes $1.5 million in clinical and regulatory services to support further development of EP-100. In addition, all existing institutional investors in Esperance -- Louisiana Fund I, Themelios Ventures, Research Corporation Technologies and Advantage Capital Partners/Louisiana Technology Fund -- as well as current and new private investors participated in the syndicate.

"We are extremely pleased to welcome Sanofi as an investor and strategic partner to Esperance and we are grateful for the unanimous, continued support of our current investors," said Hector Alila, PhD, President and CEO of Esperance Pharmaceuticals. "We believe the quality of this syndicate speaks directly to the significant potential of our pipeline and we look forward to being able to deliver on the clinical promise of EP-100 and our CLYP™ platform technology."

"Esperance has made great strides over the last few years building an impressive, proprietary technology platform with broad-based application and bringing forth strong therapeutic candidates to its pipeline," said Joseph F. Lovett, Chairman of the Board of Esperance and Managing General Partner at Louisiana Fund I. "I am pleased to continue to be part of the progress moving forward and I believe the caliber of investors involved in this syndicate, particularly Sanofi, is a significant accomplishment for Esperance and speaks to the strength of the growing biotech community in this region."

Esperance is using its CLYP™ technology to develop a robust portfolio of novel targeted membrane-disrupting peptides (tMDPs) to selectively destroy cancer cells that express target receptors. EP-100, the lead candidate, is designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces and is currently in a Phase 1 study in patients with advanced solid tumors. LHRH receptors are over-expressed in a wide range of human cancers including breast, prostate, endometrial, pancreatic, ovarian, skin, testicular and blood cancers. In addition to EP-100, Esperance has other drug candidates in preclinical stages of development, all of which have a unique targeting mechanism of action whereby candidates bind specifically and exclusively to surface antigens or receptors on cancer cells.

About Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is a clinical stage company developing a new class of targeted anticancer drugs using its Cationic Lytic Peptide (CLYP™) platform technology. These drug candidates, called targeted membrane-disrupting peptides (tMDPs) and antibody drug conjugates (ADCs) selectively seek and destroy cancer cells, including cells known to be resistant to chemotherapeutic drugs, without harming normal cells. Targeting occurs through binding to specific receptors and antigens on the cell's surface. The Company was founded on patented technology discovered by scientists at the Pennington Biomedical Research Center, the Louisiana State (LSU) Ag Center and LSU main campus. Founding investors include the Louisiana Fund I, Themelios Ventures and Research Corporation Technologies. Additional investors include Sanofi, Advantage Capital Partners/Louisiana Technology Fund and private investors. More information can be found at

SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... has found that immunotherapy can be efficiently ...
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... ProSidebar: Fashion is a set of 30 kinetic edge graphics ... editors can easily add an informative sidebar to any FCPX production. Create lists, ... self-animating drop zones, lines, bars, and text with the ease of FCPX's drag and ...
(Date:11/27/2015)... ... 2015 , ... The moment you stop improving is the ... the needs of advisers and clients but going above and beyond to find ... service. However, there's always room for improvement, which is why the entire Consulting ...
(Date:11/27/2015)... ... , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his search ... one of Joplin's most famous and beautiful concert posters. The concert was held on ... Arbor. The According to Hawley, "It is hard to believe that Joplin's stardom was ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced ... franchise owner, Somu now offers travelers, value and care based Travel Services, including ... sales, as well as, cabin upgrades and special amenities such as, shore excursions, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings Final ... ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, ... giving users limitless opportunities to stylize and create designs quickly and easily, all ...
Breaking Medicine News(10 mins):